MA-CAMBRIDGE-SEMANTICS
16.7.2020 14:02:15 CEST | Business Wire | Press release
Cambridge Semantics, the leading provider of modern, graph-driven data integration for the enterprise data fabric, today announced that Merck KGaA, Darmstadt, Germany and its US-based biopharmaceutical business EMD Serono, have selected Cambridge Semantics as its data fabric provider.
Through this multi-year agreement, Cambridge Semantics will help Merck KGaA, Darmstadt, Germany establish an enterprise data fabric to support multiple data management initiatives. Cambridge Semantics’ Anzo® platform will enable Merck KGaA, Darmstadt, Germany to deliver on immediate data-driven requirements, including regulatory compliance with Identification of Medicinal Products (IDMP), while establishing a future-proof data strategy by driving further value from data and analytics.
“New regulatory requirements necessitate innovative approaches to data management,” said Jörg Werner, Associate Director Regulatory Data Governance at Merck KGaA, Darmstadt, Germany. “We selected Cambridge Semantics over other software vendors because Anzo’s underlying technology, which is based on semantics graph data models, aligns well with our data strategy to integrate and access information across research and development.”
Cambridge Semantics and Merck KGaA, Darmstadt, Germany delivered the first production solution in December 2019 focused on harmonizing and standardizing terminologies for regulatory compliance. The teams are now partnering to expand the regulatory data fabric with data from several legacy systems to provide unprecedented and comprehensive access to regularly data objects and accelerate its strategic Veeva implementation.
Cambridge Semantics’ Anzo provides a modern, graph-driven data integration platform to connect and bring meaning to all enterprise data and enable virtually anyone in an organization – from skilled data scientists to novice business users – to develop analytics-ready data sets that combine any data from any system across the enterprise. Anzo drives digital transformation and enables deep business insights when an organization’s data is highly distributed, vastly siloed, complex and when users want answers to unanticipated questions at scale and speed.
Moritz Kloft, IT Product Manager at Merck KGaA, Darmstadt, Germany added, “While we had multiple platform choices, including several based on semantics and ontology, only Cambridge Semantics has the technology, team and vision to deliver an enterprise-scale platform to support our data-driven research and development roadmap.”
“The pharmaceutical industry faces some of the most complex, critical and broad data challenges and requirements affecting business today, and it’s an industry in which having the right data can save lives,” said Chuck Pieper, Chairman and Chief Executive Officer at Cambridge Semantics. “We are incredibly proud that Merck KGaA, Darmstadt, Germany has selected Cambridge Semantics as their data management partner. We are confident that the work we do together will be transformative in building a rich data fabric and gathering new insights that Merck KGaA, Darmstadt, Germany can use for decision-making across R&D.”
Ben Szekely, Senior Vice President of Field Operations at Cambridge Semantics added, “The scale and rich history of innovation in technology R&D of Merck KGaA, Darmstadt, Germany offers the limitless potential to realize and expand our vision for the enterprise data fabric. We look forward to advancing our product roadmap and Europe-based service offerings in support of data integration and analytics initiatives of Merck KGaA, Darmstadt, Germany.”
About Cambridge Semantics
Cambridge Semantics Inc. is a modern, graph-driven data integration and analytics software company that enables seamless access to all enterprise data. Cambridge Semantics was recently recognized as a leader in Forrester Research’s Enterprise Data Fabric Wave.
The company delivers products and solutions that enable IT departments and business users across Life Sciences, Healthcare, Financial Services, Government, Manufacturing, and other industries to accelerate data delivery and to provide meaningful insights across the organization at speed and scale.
Cambridge Semantics is based in Boston, Massachusetts.
For more information visit www.cambridgesemantics.com or follow us on Facebook, LinkedIn, and Twitter: @CamSemantics.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
The company holds the rights to the name and trademark “Merck” internationally except for the United States and Canada, where it operates in the biopharma market as EMD Serono, in life science as MilliporeSigma, and in the specialty chemicals and high/tech materials business area as EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005180/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer11.8.2026 14:30:00 CEST | Press release
Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business OfficerAppointments deepen vaccine development expertise and enhance global commercial and strategic leadership ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisition by Merck; and Bill Warren, former Global Head of Antigen Design at Sanofi Vaccines, as independent members of ILiAD’s Board of Directors. The Company also announced the appointment of Antony Blanc, former VP, Head of Global Marketing and Global Strategic Pricing at GSK Vaccines, as Chief Business Officer. “Our recently appointed colleagues bring an extraordinary depth of experience in vaccine development, global commercialization, and strate
TEC reduces pressure on support teams with proactive outage communications powered by Adtran and GOCare11.8.2026 14:15:00 CEST | Press release
News summary: Fiber broadband providers need faster, more transparent ways to manage outages and reduce support surges TEC is now using GOCare OutageIQ integrated with Adtran’s outage notification API and Mosaic One to automate subscriber messaging Open APIs turn network insight into actionable workflows, improving responsiveness and operational efficiency Adtran and GOCare today announced that Telephone Electronics Corporation (TEC) has improved outage responses and reduced inbound support tickets using GOCare’s OutageIQ solution integrated with Adtran’s outage notification API and Mosaic One. Serving communities across Mississippi, Alabama and Tennessee, TEC delivers fiber broadband services built on a foundation of community investment and reliable service. By combining proactive notifications with real-time network insights, the service provider can now inform customers as issues are detected while equipping support teams with immediate context. This transparency helps build subscr
Kinaxis-Sponsored Study Identifies Supply Chain AI Accountability Gap Amidst Rapid Adoption Expectations11.8.2026 14:07:00 CEST | Press release
Trust, measurable outcomes, and governance lag, even as 41% expect autonomous-at-scale operations within two years Kinaxis® (TSX:KXS), a global leader in supply chain orchestration, today announced the findings of new independent research from IDC. The IDC InfoBrief, sponsored by Kinaxis, “Making Supply Chain AI Accountable,” reveals a growing chasm between organizations’ aggressive ambitions for autonomous AI adoption and their readiness to hold these advanced systems - which we believe underscores the need for a disciplined approach to AI investment and deployment to prevent costly failures and deliver measurable business value. What This Means for Supply Chain Leaders The IDC InfoBrief, which surveyed more than 2,000 supply chain leaders across nine global markets, found that while AI adoption is nearly universal - only 2% of respondents report no AI-enabled capabilities, and just 12% consider themselves AI leaders. Over half (52%) cite trust in AI-driven decisions as a top barrier
One in Four Executives Say AI Errors Have Reached External Audiences or Boards, According to New Research From Workiva11.8.2026 14:00:00 CEST | Press release
Although 84% of executives are at least somewhat confident in AI output without human review, only 11% believe their data quality is sufficient for AI use Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today released findings from its 2026 Midyear Executive Benchmark Survey. Although 84% of surveyed executives say they are at least somewhat confident in the accuracy of AI output without human review, one in four (26%) say internal audits have detected AI errors that reached external audiences or board members. This data suggests there is a disconnect between what executives believe and what evidence shows. As AI reshapes the enterprise at unprecedented speed, a new risk is emerging: transformation could be outpacing the instincts of the leaders tasked with overseeing it. "Confidence in AI without control over data quality is a liability, not a strategy. CFOs need platforms that connect AI to trusted, auditable data so every output
Altasciences Continues to Expand North American Bioanalytical Footprint11.8.2026 14:00:00 CEST | Press release
Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom